Vorinostat
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Vorinostat.svg | |
| Vorinostat
| |
| Systematic (IUPAC) name | |
| N-hydroxy-N'-phenyl-octanediamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H20N2O3 |
| Mol. mass | 264.32 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 71% |
| Metabolism | Hepatic glucuronidation and oxidation CYP system not involved |
| Half life | 2 hours |
| Excretion | Renal (negligible) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
D(US) |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Vorinostat | |
|
Articles | |
|---|---|
|
Most recent articles on Vorinostat | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Vorinostat at Clinical Trials.gov Clinical Trials on Vorinostat at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Vorinostat
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Vorinostat Discussion groups on Vorinostat Patient Handouts on Vorinostat Directions to Hospitals Treating Vorinostat Risk calculators and risk factors for Vorinostat
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Vorinostat | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), brand name Zolinza®, is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors.
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.
References
- Merck & Co. (June 7, 2006). ZOLINZA™, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration. Press release. Retrieved on 2006-10-06.
- Food and Drug Administration (October 6, 2006). FDA Approves New Drug for Skin Cancer, Zolinza. Press release. Retrieved on 2006-10-06.
- Mayo Clinic (June 3, 2007). Vorinostat shows anti-cancer activity in recurrent gliomas. Press release. Retrieved on 2007-06-03.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
